Australia markets closed

ABUS Jan 2025 4.500 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.3000-0.0500 (-14.29%)
At close: 01:38PM EDT
Full screen
Previous close0.3500
Open0.3000
Bid0.2500
Ask0.3500
Strike4.50
Expiry date2025-01-17
Day's range0.3000 - 0.3000
Contract rangeN/A
Volume1
Open interest637
  • Zacks

    Has Arbutus Biopharma (ABUS) Outpaced Other Medical Stocks This Year?

    Here is how Arbutus Biopharma (ABUS) and Astrazeneca (AZN) have performed compared to their sector so far this year.

  • Zacks

    Are Medical Stocks Lagging HCA Healthcare (HCA) This Year?

    Here is how HCA Healthcare (HCA) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.

  • GlobeNewswire

    Arbutus to Participate in Two Upcoming Investor Conferences

    WARMINSTER, Pa., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Arbutus management team will participate in and host one-on-one meetings at the following two upcoming investor conferences which are being held in New York: H.C. Wainwrigh